|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage显示文摘AIM To describe magnetic resonance(MR) imaging features of pancreatic neuroendocrine neoplasms(Pan NENs) according to their grade and tumor-nodes-metastases stage by comparing them to histopathology and todetermine the accuracy of MR imaging features in predicting their biological behavior.METHODS This study was approved by our institutional review board; requirement for informed patient consent was waived due to the retrospective nature of the study. Preoperative MR examinations of 55 Pan NEN patients(29 men, 26 women; mean age of 57.6 years, range 21-83 years) performed between June 2013 and December 2015 were reviewed. Qualitative and quantitative features were compared between tumor grades and stages determined by histopathological analysis.RESULTS Ill defined margins were more common in G2-3 and stage Ⅲ-Ⅳ PanN ENs than in G1 and low-stage tumors(P < 0.001); this feature had high specificity in the identification of G2-3 and stage Ⅲ-Ⅳ tumors(90.3% and 96%, 95%CI: 73.1-97.5 and 77.7-99.8). The mean apparent diffusion coefficient value was significantly lower in G2-3 and stage Ⅲ-Ⅳ lesions compared to well differentiated and low-stage tumors(1.09 × 10-3 mm2/s vs 1.45 × 10-3 mm2/s and 1.10 × 10-3 mm2/s vs 1.53 × 10-3 mm2/s, P = 0.003 and 0.001). Receiving operator characteristic analysis determined optimal cutoffs of 1.21 and 1.28 × 10-3 mm2/s for the identification of G2-3 and stage Ⅲ-Ⅳ tumors, with sensitivity and specificity values of 70.8/80.7% and 64.5/64%(95%CI: 48.7-86.6/60-92.7 and 45.4-80.2/42.6-81.3).CONCLUSION MR features of PanN ENs vary according to their grade of differentiation and their stage at diagnosis and could predict the biological behavior of these tumors. | Riccardo De Robertis Sara Cingarlini Paolo Tinazzi Martini Silvia Ortolani Giovanni Butturini Luca Landoni Paolo Regi Roberto Girelli Paola Capelli Stefano Gobbo Giampaolo Tortora Aldo Scarpa Paolo Pederzoli Mirko D'Onofrio | 2017 | World Journal of Gastroenterology2017，23，2： | 16 |
| 2 | Prognostication and response assessment in liver and pancreatic tumors:The new imaging显示文摘Diffusion-weighted imaging(DWI), dynamic contrastenhanced magnetic resonance imaging(DCE-MRI) and perfusion computed tomography(CT) are technical improvements of morphologic imaging that can evaluate functional properties of hepato-bilio-pancreatic tumors during conventional MRI or CT examinations.Nevertheless, the term 'functional imaging' is commonly used to describe molecular imaging techniques, as positron emission tomography(PET)CT/MRI, which still represent the most widely used methods for the evaluation of functional properties of solid neoplasms; unlike PET or single photon emission computed tomography, functional imaging techniques applied to conventional MRI/CT examinations do not require the administration of radiolabeled drugs or specific equipments. Moreover, DWI and DCE-MRI can be performed during the same session, thus providing a comprehensive 'one-step' morphological and functional evaluation of hepato-bilio-pancreatic tumors. Literature data reveal that functional imaging techniques could be proposed for the evaluation of these tumors before treatment, given that they may improve staging and predict prognosis or clinical outcome. Microscopic changes within neoplastic tissues induced by treatments can be detected and quantified with functional imaging,therefore these techniques could be used also for posttreatment assessment, even at an early stage. The aim of this editorial is to describe possible applications of new functional imaging techniques apart frommolecular imaging to hepatic and pancreatic tumors through a review of up-to-date literature data, with a particular emphasis on pathological correlations,prognostic stratification and post-treatment monitoring. | Riccardo De Robertis Paolo Tinazzi Martini Emanuele Demozzi Gino Puntel Silvia Ortolani Sara Cingarlini Andrea Ruzzenente Alfredo Guglielmi Giampaolo Tortora Claudio Bassi Paolo Pederzoli Mirko D'Onofrio | 2015 | World Journal of Gastroenterology2015，21，22： | 10 |
| 3 | Management of single pulmonary metastases from colorectal cancer:State of the art显示文摘Colorectal cancer(CRC)is one of the most common causes of death from cancer.Lung seeding occurs in approximately 10%of patients surgically treated for primary CRC with radical intent:the lung is the most common site of metastases after the liver.While surgical treatment of liver metastases is widely accepted to affect long-term outcomes,more controversial and not standardized is the therapy for CRC patients developing lung metastases.Experience suggests the potential curative role of pulmonary metastasectomy,especially in oligometastatic disease.However,the optimal strategy of care and the definition of prognostic factors after treatment still need to be defined.This review focused on the uncommon scenario of single pulmonary metastases from CRC.We explored pertinent literature and provide an overview of the epidemiology,clinical characteristics and imaging of single pulmonary metastases from CRC.Additionally,we identified the best available evidence for overall management.In particular,we analyzed the role and results of locoregional approaches(surgery,radiotherapy or ablative procedures)and their integration with systemic therapy. | Marco Chiappetta Lisa Salvatore Maria Teresa Congedo Maria Bensi Viola De Luca Leonardo PetraccaCiavarella Floriana Camarda Jessica Evangelista Vincenzo Valentini Giampaolo Tortora StefanoMargaritora Filippo Lococo | 2022 | World Journal of Gastrointestinal Oncology2022，14，4： | 2 |
| 4 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 5 | CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors显示文摘 | Matteo Santoni Sergio Bracarda Massimo Nabissi Francesco Massari Alessandro Conti Emilio Bria Giampaolo Tortora Giorgio Santoni Stefano Cascinu Yi-Fang Ping | 2014 | BioMed Research International2014，，： | 1 |
| 6 | Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials显示文摘 | Matteo Santoni Alessandro Conti Francesco Massari Giorgio Arnaldi Roberto Iacovelli Mimma Rizzo Ugo Giorgi Laura Trementino Giuseppe Procopio Giampaolo Tortora Stefano Cascinu | 2015 | Int. J. Cancer2015，，： | 1 |
| 7 | A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor 显示文摘 | Fortunate Ciardiello Giampaolo Tortora | 2001 | Clinical Cancer Res2001，7，10： | 1 |
| 8 | ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung显示文摘 | Anna Caliò Alessia Nottegar Eliana Gilioli Emilio Bria Sara Pilotto Umberto Peretti Stefania Kinspergher Francesca Simionato Serena Pedron Sakari Knuutila Giampaolo Tortora Albino Eccher Antonio Santo Luca Tondulli Giorgio Inghirami Fabrizio Tabbò Guido M | 2014 | Journal of Thoracic Oncology2014，，： | 1 |
| 9 | Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma显示文摘 | Matteo Santoni Francesco Massari Consuelo Amantini Massimo Nabissi Francesca Maines Luciano Burattini Rossana Berardi Giorgio Santoni Rodolfo Montironi Giampaolo Tortora Stefano Cascinu | 2013 | Cancer Immunology Immunotherapy2013，，12： | 1 |
| 10 | Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839 (Iressa)显示文摘 | Cataldo Bianco Giampaolo Tortora Roberto Bianco | 2002 | Clin Cancer Res2002，8，： | 1 |
| 11 | “Targeting” renal cell carcinoma patients with “targeted” agents: Are we there yet?显示文摘The rapid approval of several novel agents, targeting the vascular endothelial growth factor or mammalian target of rapamycin pathways(sunitinib, pazopanib, sorafenib, axitinib, bevacizumab, everolimus, temsirolimus) has given to metastatic renal cell carcinoma(m RCC) patients and their treating physicians many new and effective therapeutic options. The treatment paradigm for these patients is rapidly evolving, with future studies needed to defi ne the optimal sequencing of these new agents. Despite progresses, no validated biomarkers able to predict clinical outcome or useful to guide patient selection for treatment are currently available. Recent studies have suggested that some biomarkers, including cytokines, circulating proangio-genic factors, markers of hypoxia or targets of signaling pathways are potentially promising prognostic or predictive factors in m RCC. We present an overview of the most recent developments in identifying biomarkers for targeted therapies in advanced RCC. | Francesca Maines Sara Pilotto Michele Milella Francesco Massari Vanja Vaccaro Alessandra Felici Emilio Bria Giampaolo Tortora | 2014 | World Journal of Clinical Urology2014，3，1： | 0 |
| 12 | Neoadjuvant treatment:A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma显示文摘Patients affected by pancreatic ductal adenocarcinoma(PDAC)frequently present with advanced disease at the time of diagnosis,limiting an upfront surgical approach.Neoadjuvant treatment(NAT)has become the standard of care to downstage non-metastatic locally advanced PDAC.However,this treatment increases the risk of a nutritional status decline,which in turn,may impact therapeutic tolerance,postoperative outcomes,or even prevent the possibility of surgery.Literature on prehabilitation programs on surgical PDAC patients show a reduction of postoperative complications,length of hospital stay,and readmission rate,while data on prehabilitation in NAT patients are scarce and randomized controlled trials are still missing.Particularly,appropriate nutritional management represents an important therapeutic strategy to promote tissue healing and to enhance patient recovery after surgical trauma.In this regard,NAT may represent a new interesting window of opportunity to implement a nutritional prehabilitation program,aiming to increase the PDAC patient’s capacity to complete the planned therapy and potentially improve clinical and survival outcomes.Given these perspectives,this review attempts to provide an in-depth view of the nutritional derangements during NAT and nutritional prehabilitation program as well as their impact on PDAC patient outcomes. | Ilaria Trestini Marco Cintoni Emanuele Rinninella Futura Grassi Salvatore Paiella Roberto Salvia Emilio Bria Carmelo Pozzo Sergio Alfieri Antonio Gasbarrini Giampaolo Tortora Michele Milella Maria Cristina Mele | 2021 | World Journal of Gastrointestinal Surgery2021，13，9： | 0 |
| 13 | Double tracer PET/CT:what is it and what does it mean?显示文摘^(68)Ga-DOTA-peptide PET/CT is a recommended imaging modality in the workup of neuroendocrine neoplasms(NENs),which shows high diagnostic sensitivity and is a strong predictor of successful somatostatin receptor directed treatments.Although not routinely recommended,reliable evidences show that^(18)F-FDG PET/CT can provide complementary information in this setting with the ability to discriminate slow-proliferating tumors from aggressive,rapidly-proliferating tumors.Further,it has been proposed as an independent prognostic factor for the prediction of either overall survival or progression free survival.In this review,we provide insight into the biologic significance of ^(68)Ga-DOTA-peptides and ^(18)F-FDG uptake,and of the use of double tracer(^(68)Ga-DOTA-peptides plus ^(18)F-FDG)PET/CT in the clinical evaluation of patients affected by NENs. | Mattia Pellicciari Silvia Ortolani Elisabetta Grego Giampaolo Tortora Sara Cingarlini | 2016 | Journal of Cancer Metastasis and Treatment2016，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员